Showing papers in "Cancer Treatment Reviews in 2006"

TL;DR: The state of the art of treatment for bone osteosarcoma in the pediatric age is reviewed, with the most effective drugs still the same as those employed over the last 20 years as front line neoadjuvant or adjuvant chemotherapy: Doxorubicin, Cisplatin, Methotrexate, Ifosfamide.

TL;DR: The most effective approach to laryngeal cancer remains prevention and early diagnosis when this cancer is curable with function preserving treatments.

TL;DR: According to available data, opioid switching results in clinical improvement in more than 50% of patients with chronic pain with poor response to one opioid, however, data are based on open studies or small case series.

TL;DR: Evidence indicating that the in vivo anti-cancer efficacy of HDACIs is at least in part dependent on suppression of cancer cell migration, invasion, metastasis, blood supply, and angiogenesis is summarised.

TL;DR: The HER1/EGFR tyrosine kinase inhibitors erlotinib and gefitinib are in advanced clinical development for glioma, and a number of trials are in progress, or have recently been completed.

TL;DR: Questions concerning the role of PET in target volume delineation, both for the primary tumour and regional lymph nodes and does it improve the outcome of radiotherapy, are addressed.

TL;DR: In the first-line treatment of metastatic CRC, the results of two prospective, multicenter phase III trials have shown that the combination of irinotecan with bolus or infusional 5-fluorouracil (5FU)/leucovorin (LV) can significantly prolong survival compared with 5FU/LV alone, with a manageable side effects profile.

TL;DR: Although trastuzumab is able to produce a low response rate as a single agent in pretreated ovarian cancer patients with overexpression of HER2, its usefulness is limited due to the low frequency of strong expression.

TL;DR: This overview presents the up-to-date evidence on colposcopy practice and other diagnostic modalities such as HPV DNA test and cytology for cervical intraepithelial neoplasia (CIN) and suggests a promising combination for the early detection of treatment failures due to residual disease.

TL;DR: This review summarizes the recent advances in understanding the mechanisms for COX-2-derived PG signaling in hepatocarcinogenesis and focuses on the newly unveiled interactions between PG cascade and other key signaling pathways that coordinately regulate HCC growth.

TL;DR: Six months to one year after RT, taste acuity recovers to its previous level in many patients, but some patients show incomplete or no recovery even several years later, and the late-radiation effects can probably be reduced, but the remaining sequelae are still bothersome to the patients.

TL;DR: Early results suggest that acute toxicity is acceptable, planned surgery after such treatment is feasible, and that further evaluation of such combined modality treatment is warranted.

TL;DR: Systemic infusion chemotherapies based on 5-fluorouracil (5-FU), oxaliplatin (OHP) and irinotecan (CPT-11) are well tolerated and have been shown to be effective in non-operable patients, giving them a probability of survival at five years similar to that of patients operated on at diagnosis.

TL;DR: A critical review of research on the signaling mechanisms induced by MSAs, their relevance to apoptosis, and their potential for exploitation by combinatorial therapy is presented.

TL;DR: Multimodal treatment seems to be the best way to optimize TACE outcomes in HCC, as a combined approach involving TACE and percutaneous ablation improves survival.

TL;DR: Positive results of an otoprotector in clinical practice may increase the effectiveness of cisplatin therapy and can improve the quality of life for a large group of patients.

TL;DR: O6-BG has been found to enhance the cytotoxicity of agents that do not form adducts at the O6-position of DNA, including platinating agents and its mechanism of action with these agents is not fully understood.

TL;DR: This review summarizes the literature concerning the relationship between angiogenesis and progression in HCC and the recent applications of anti-angiogenic agents which interfere or block HCC progression are reviewed.

TL;DR: Experimental studies show that at high locoregional concentrations there seems to be such an effect of thermal enhancement of taxane cytotoxicity, and feasibility and efficacy of this treatment have evidently been demonstrated in various clinical studies.

TL;DR: Chemotherapeutic modulation of HIF-1 pathways has shown promise for patients with chemo-radio resistant or recurrent tumours in Phase II clinical trials and the existing literature on hypoxia inducible factor-1α, particularly its role in carcinogenesis and clinical implications of its over-expression are reviewed.

TL;DR: Preliminary observations suggest that monoclonal antibodies - rituximab and BL-22 immunotoxin are highly active in this disorder even refractory to 2-CdA.

TL;DR: The use of purine analogues augments the risk for grade III/IV infections and haemolytic anaemia and was not able to detect a statistically significant improvement of overall survival compared to alkylator-based regimens.

TL;DR: The state-of-the-art of conventional treatments for STS are reviewed and the most promising findings in the development of molecularly targeted therapeutic approaches are summarized.

TL;DR: The exciting results observed with the combination of vinorelbine and trastuzumab in patients with Her-2 overexpressing/amplified tumours, as well as the development of a reliable formulation and revised schedule of oral vinORElbine with proven activity in ABC appear to have revived the interest in this compound in the management of this disease.

TL;DR: The major hormonal differences between male and female breast cancer that would suggest the need to explore different treatment strategies if significant advances are to be made in the understanding and treatment of this distinct disease are focused on.

TL;DR: The significant benefit in grade 3-4 neutropenia seems to suggest this approach in patients with NSCLC pretreated for advanced disease, although considering all drawbacks related to literature-based meta-analyses, weekly docetaxel seems not to improve survival when compared to 3-weekly docetAXel.

TL;DR: Adding SRS to WBRT improves survival in patients with one brain metastasis, and combining SRS and W BRT improves local tumour control and functional independence in all patients.

TL;DR: The aim of this review is to discuss the systemic management of AIDS-KS, with special focus on the above mentioned questions.

TL;DR: In this paper, the authors conducted a review of the available literature concerning the use of adjuvant chemotherapy, palliative chemotherapy and surgery in elderly patients with colorectal cancer, using data from meta-analyses, non-systematic reviews and individual trials.

TL;DR: Prophylactic CSFs significantly decrease the incidence of FN and the durations of severe neutropenia, hospitalization, and antibiotic use in pediatric cancer patients, but they do not significantly decrease documented infections.